- Home
- GTEC vs CVKD Comparison
GTEC vs CVKD Comparison
Compare GTEC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | CVKD |
|---|---|---|
| Founded | 2006 | 2022 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 17.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | GTEC | CVKD |
|---|---|---|
| Price | $0.72 | $7.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 132.7K | 50.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $1.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $4.91 |
| 52 Week High | $2.58 | $20.39 |
Technical Indicators
Market Signals| Indicator | GTEC | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 50.25 |
| Support Level | $0.66 | $6.64 |
| Resistance Level | $1.16 | $8.87 |
| Average True Range (ATR) | 0.06 | 0.65 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 37.32 | 31.46 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.